JP2005509597A5 - - Google Patents

Download PDF

Info

Publication number
JP2005509597A5
JP2005509597A5 JP2003519439A JP2003519439A JP2005509597A5 JP 2005509597 A5 JP2005509597 A5 JP 2005509597A5 JP 2003519439 A JP2003519439 A JP 2003519439A JP 2003519439 A JP2003519439 A JP 2003519439A JP 2005509597 A5 JP2005509597 A5 JP 2005509597A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
1racp
composition according
receptor
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003519439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005509597A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/024948 external-priority patent/WO2003014309A2/en
Publication of JP2005509597A publication Critical patent/JP2005509597A/ja
Publication of JP2005509597A5 publication Critical patent/JP2005509597A5/ja
Pending legal-status Critical Current

Links

JP2003519439A 2001-08-07 2002-08-07 疾患の治療におけるインターロイキン−1受容体 Pending JP2005509597A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31078901P 2001-08-07 2001-08-07
PCT/US2002/024948 WO2003014309A2 (en) 2001-08-07 2002-08-07 Interleukin-1 receptors in the treatment of diseases

Publications (2)

Publication Number Publication Date
JP2005509597A JP2005509597A (ja) 2005-04-14
JP2005509597A5 true JP2005509597A5 (enExample) 2006-01-05

Family

ID=23204113

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003519439A Pending JP2005509597A (ja) 2001-08-07 2002-08-07 疾患の治療におけるインターロイキン−1受容体

Country Status (8)

Country Link
US (1) US20030049255A1 (enExample)
EP (1) EP1450837A4 (enExample)
JP (1) JP2005509597A (enExample)
AU (1) AU2002324625B2 (enExample)
CA (1) CA2456762A1 (enExample)
MX (1) MXPA04001187A (enExample)
PL (1) PL374118A1 (enExample)
WO (1) WO2003014309A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU740405B2 (en) * 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7771719B1 (en) * 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US20040043397A1 (en) * 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7718397B2 (en) * 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US20090035261A1 (en) * 2000-03-21 2009-02-05 Jian Chen IL-17 homologous polypeptides and therapeutic uses thereof
US20030180255A1 (en) * 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20030203451A1 (en) * 2000-08-24 2003-10-30 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20030096969A1 (en) * 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
WO2005010044A2 (en) 2003-07-08 2005-02-03 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
WO2005049056A2 (en) * 2003-11-14 2005-06-02 Ucl Biomedica Plc Immune modulator comprising whole cell rhodococcus, gordonia, nocardia, dietzia, tsukamurella or nocardioides bacteria
SI1983000T1 (sl) 2003-11-21 2015-12-31 Ucb Biopharma Sprl Postopek za zdravljenje multiple skleroze z zaviranjem aktivnosti il-17
ES2395087T3 (es) * 2004-05-05 2013-02-08 Valorisation-Recherche, Société en Commandite Antagonistas del receptor de interleuquina-1, composiciones y métodos de tratamiento
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
AU2006230419A1 (en) * 2005-03-31 2006-10-05 Targeted Genetics Corporation Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
WO2007004060A2 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
EP2848258B1 (en) 2005-10-26 2017-12-13 Novartis AG Treatment of familial Mediterranean Fever with anti IL-1beta antibodies
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
JP2009183176A (ja) * 2008-02-05 2009-08-20 Univ Of Tokyo Il−1タイプiiレセプター遺伝子の欠損変異体マウス
CA2721713C (en) * 2008-05-05 2019-07-09 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
JP5622720B2 (ja) * 2008-05-21 2014-11-12 ニューロテスインコーポレイテッド 神経原繊維変化に関連する進行性認知障害の治療方法
EP2427203B1 (en) * 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f antibodies and use thereof
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
ES2703774T3 (es) 2010-06-18 2019-03-12 Xbiotech Inc Tratamiento para la artritis
WO2012098407A1 (en) 2011-01-19 2012-07-26 Cantargia Ab Anti - il1rap antibodies and their use for treating human
US9724409B2 (en) * 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
EP2928916B1 (en) 2012-12-10 2019-03-13 Vib Vzw Novel interleukin-33 inhibitors
CN108026172B (zh) 2015-06-26 2022-04-29 赛诺菲生物技术公司 单克隆抗il-1racp抗体
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
US11633425B2 (en) 2021-05-13 2023-04-25 Ahava—Dead Sea Laboratories Ltd. Anti-glycation compositions
EP4590704A1 (en) 2022-09-21 2025-07-30 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use
US20260015427A1 (en) 2024-06-25 2026-01-15 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
WO1991018982A1 (en) * 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) * 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
EP0670730B1 (en) * 1992-03-30 2003-06-04 Immunex Corporation Fusion protein comprising two tumor necrosis factor receptors
PE64396A1 (es) * 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
CA2297176A1 (en) * 1997-04-24 1998-10-29 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory diseases
EP2241328A1 (en) * 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
WO2002064630A2 (en) * 2000-10-31 2002-08-22 Immunex Corporation Il-1 receptor accessory protein

Similar Documents

Publication Publication Date Title
US4783465A (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
Vane et al. Inflammation and the mechanism of action of anti‐inflammatory drugs
ES2659205T3 (es) Uso de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il)piperidin-2,6-diona en el tratamiento de enfermedades inflamatorias y relacionadas con el sistema inmune
ES2257757T3 (es) Carboxilato de terfenadina y el tratamiento de trastornos alergicos.
Sihra et al. Effect of cyclosporin A on the allergen-induced late asthmatic reaction.
US6492364B1 (en) Triazolo and derivatives as chemokine inhibitors
US20090192094A1 (en) Treatment of diseases using ice inhibitors
JP2003512429A (ja) デスロラタジンを用いた睡眠障害処置
WO2003014309A2 (en) Interleukin-1 receptors in the treatment of diseases
AU2002324625A1 (en) Interleukin-1 receptors in the treatment of diseases
US20120114645A1 (en) Use of il-1 antagonists to treat pseudogout
JP2004525157A (ja) Aidsの処置に有用なccr5アンタゴニスト
Owen et al. Methotrexate in Reiter's disease.
Kudlacz et al. Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule α4β1 antagonists
JP2005526053A5 (enExample)
JP2002501039A (ja) Vla−4アンタゴニスト
JP2005532256A5 (enExample)
JP4139453B2 (ja) 細胞接着阻害剤
US20030225054A1 (en) Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
JP2002538114A (ja) Copdの治療方法
JP2002326936A5 (enExample)
Kazmierski et al. Small molecule CCR5 and CXCR4-based viral entry inhibitors for anti-HIV therapy currently in development
WO2021213287A1 (zh) Irak4抑制剂治疗ali/ards中的应用
Sasaki et al. Treatment of severe psoriasis with low dose cyclosporin A and the effect on the helper‐suppressor T cell ratio in peripheral blood
JPWO2004032964A1 (ja) アレルギー性疾患治療剤